Rethinking Averages: Why They Mislead and How to Make Better Decisions | Sharon Zicherman | TED

The Personal Impact of Averages

• 💡 At 39, Sharon Zicherman was diagnosed with Stage 3C colorectal cancer, facing a 50 percent chance of surviving more than five years.
• 🎯 This statistic felt paralyzing because it included individuals with vastly different lifestyles, ages, and health histories, not reflecting her specific situation.
• 🧠 This personal experience prompted a fundamental shift in her thinking about how averages are used, especially in critical life moments.

Questioning the Average Metric

• ❓ The first crucial question is whether the average is the right metric for a given situation, particularly when managing risk.
• 🏗️ The Burj Khalifa was designed to withstand a magnitude 7.0 earthquake, far exceeding the average of 4.0 in the region, to ensure safety.
• 🎬 Similarly, choosing a scary movie based on the average age of the household led to a sleepless night for a six-year-old, demonstrating how the average can be inappropriate.

Selecting the Right Average

• ❓ The second question is whether you are considering the right average.
• 🚑 While AEDs are rarely used on average, their value lies in the potential impact during a cardiac arrest, where survival rates dramatically increase with immediate use.
• 🩺 For cancer, the average survival rate didn't account for her age (over 10 years younger than the typical patient) or recent treatment advancements, highlighting the need for a more relevant average.

Considering Outliers and the Unseen

• ❓ The third question is: What are you missing by focusing on the average?
• 📈 Firms that survived the subprime mortgage crisis analyzed worst-case scenarios and outliers, not just average default rates.
• ✨ Dr. Jeffrey Rediger's research into spontaneous remissions suggests that studying outlier cases can provide valuable insights, even if they defy statistical norms.
• ✅ By moving beyond the average and considering outliers, individuals can receive tailored treatments rather than generic ones, aiming for 100 percent survivorship.